Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halcinonide SCHEMBL5188866 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL10019829 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL7861670 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL4335 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL4336 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL24015431 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8467031 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL5489567 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8529770 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL2843940 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4ARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | NR3C1 1/4885PGR 515/4885CYP3A4 728/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885PGR 1161/4885CYP3A4 331/4885 |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 1122/4885CYP3A4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.